Want to see JP:4565 full AI Analyst Report?
Top Page
Sosei Group
(4565)
Select Model
Select Model
Rating:47Neutral
Price Target:
¥840.00
▼(-6.98% Downside)
Action:Reiterated
Date:06/01/26
The score is primarily constrained by weak financial performance: despite strong revenue growth and high gross margins, persistent losses and negative free cash flow increase funding risk. Technicals provide modest support via price holding above longer-term moving averages, but near-term momentum is muted. Valuation is pressured by negative earnings (negative P/E) and no stated dividend yield.
Positive Factors
Revenue growth & high gross margin
Sosei's sustained revenue growth and ~72% gross margin point to durable product economics and effective cost of goods control around its discovery platform. Over months, this supports reinvestment in R&D and makes future partnerships more attractive due to compelling unit economics.
Negative Factors
Negative operating & free cash flow
Persistent negative operating and free cash flow indicate the business is not self-funding its operations, creating ongoing reliance on external financing or milestone receipts. Over 2-6 months this elevates dilution and execution risk if expected partner payments are delayed or reduced.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue growth & high gross margin
Sosei's sustained revenue growth and ~72% gross margin point to durable product economics and effective cost of goods control around its discovery platform. Over months, this supports reinvestment in R&D and makes future partnerships more attractive due to compelling unit economics.
Read all positive factors
Sosei Group (4565) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥81.13B
Dividend YieldN/A
Average Volume (3M)945.56K
Price to Earnings (P/E)―
Beta (1Y)1.10
Revenue Growth10.88%
EPS Growth-327.56%
CountryJP
Employees354
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-110.53
Shares Outstanding92,614,160
10 Day Avg. Volume1,166,890
30 Day Avg. Volume945,556
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)1.22
Price to Sales (P/S)2.52
P/FCF Ratio-23.96
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)44.45
Revenue Forecast (FY)¥40.43B
Sosei Group Business Overview & Revenue Model
Company Description
Nxera Pharma Co., Ltd., established in Tokyo, Japan, in 1990, is a biopharmaceutical enterprise focused on the discovery, development, and commercialization of pharmaceutical solutions. The company's operations extend across multiple international...
How the Company Makes Money
Sosei Group primarily makes money by discovering and developing drug candidates and then partnering (out-licensing) those programs to pharmaceutical and biotechnology companies. Under these collaboration and licensing arrangements, the company typ...
Sosei Group Earnings Call Summary
Earnings Call Date:Feb 13, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Aug 07, 2026
Earnings Call Sentiment Neutral
The call presented a mixed picture: strong commercial execution in Japan/APAC and meaningful pipeline progress (Phase II–ready assets and partner-led late-stage programs) are clear positives, supported by rising product sales and a profitable commercial unit. However, FY2025 was marked by material operating losses, a notable decline in milestone revenue, higher R&D spend, and one-off charges. Management has announced restructuring, cost-reduction targets (>10%), and a plan to refocus the U.K. discovery portfolio, with expectations that benefits will appear in H2 FY2026. Given the balance between encouraging commercial/pipeline momentum and significant near-term financial and execution risks, the overall tone is cautious and transitional: opportunities exist but require successful execution of BD, cost actions, and regulatory steps to translate into the company’s stated FY2026 profitability goals.Positive Updates
Overall Revenue Slightly Increased
Total revenue rose to JPY 29.6 billion from JPY 28.8 billion in FY2024, a modest increase of JPY 0.8 billion (~2.8% year-on-year).
Negative Updates
Significant Decline in Milestone Revenue
Milestone revenue decreased from JPY 11.2 billion in FY2024 to JPY 7.9 billion in FY2025, a drop of JPY 3.3 billion (~29.5% YoY); management cited the absence of large partner milestone events that occurred in the prior year (e.g., Neurocrine $35m milestone in 2024).
Read all updates
Q4-2025 Updates
Positive
Negative
Overall Revenue Slightly Increased
Total revenue rose to JPY 29.6 billion from JPY 28.8 billion in FY2024, a modest increase of JPY 0.8 billion (~2.8% year-on-year).
Read all positive updates
Company Guidance
The company guided to aggressive FY2026 targets: net product sales of >JPY 19.5 billion (PIVLAZ + QUVIVIQ), full‑year IFRS profitability and positive core operating profit/operating profit, plus a >10% reduction in total costs and breakeven on the drug‑discovery (platform) side on a core basis; management also aims to sign one or more high‑value BD deals, out‑license Phase II‑ready in‑house programs (NXE'149, NXE'744) by end‑FY2026 if possible, and initiate at least one new partner Phase II trial. Key FY2025 metrics underpinning the guidance: total revenue JPY 29.6bn (vs JPY 28.8bn FY2024), product sales JPY 17.8bn (up from JPY 14.0bn), milestone revenue JPY 7.9bn (down from JPY 11.2bn), core OP -JPY0.4bn and IFRS OP -JPY8.4bn; SG&A down ~4–5% (~JPY 0.8bn), R&D spend up JPY 2.7bn, one‑off restructuring/impairments ~JPY 1.8bn and bond‑term related costs ~JPY 4.6bn. Product specifics feeding 2026 plans: PIVLAZ sales JPY 13.5bn (7% YoY) with market share rising from 34% (2022) to 74% (2025) and 25,470 patients treated since launch (PIVLAZ expected >4% growth in FY2026); QUVIVIQ JPY 4.3bn (224% YoY) with a 30% revenue growth expectation in FY2026 and company guidance of JPY 5–7bn for the year; forecast assumptions for milestones were conservative (Nomura noted a milestone line of JPY 2.5bn within an assessed aggregate figure cited at JPY 40.3bn), and management expects cost and restructuring benefits to begin to flow through in H2 FY2026.Sosei Group Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
52
Neutral
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 34.23B | 29.61B | 28.84B | 12.77B | 15.57B | 17.71B |
| Gross Profit | 26.53B | 21.42B | 18.13B | 7.87B | 13.80B | 15.98B |
| EBITDA | 2.13B | -3.91B | -1.38B | -6.58B | 4.16B | 8.19B |
| Net Income | -9.98B | -12.53B | -4.84B | -7.19B | 382.00M | 1.02B |
Balance Sheet | ||||||
| Total Assets | 133.34B | 134.79B | 151.50B | 157.20B | 100.22B | 98.42B |
| Cash, Cash Equivalents and Short-Term Investments | 11.60B | 20.36B | 36.20B | 49.06B | 66.56B | 60.09B |
| Total Debt | 55.83B | 57.38B | 67.90B | 73.97B | 29.73B | 29.27B |
| Total Liabilities | 69.65B | 73.79B | 82.98B | 90.39B | 42.29B | 40.95B |
| Stockholders Equity | 63.69B | 61.00B | 68.52B | 66.81B | 57.94B | 57.47B |
Cash Flow | ||||||
| Free Cash Flow | -5.58B | -3.12B | -8.24B | -6.08B | 9.65B | 6.90B |
| Operating Cash Flow | -4.93B | -2.67B | -7.72B | -5.27B | 9.95B | 7.09B |
| Investing Cash Flow | -3.63B | 5.43B | -4.76B | -63.79B | 1.04B | 278.00M |
| Financing Cash Flow | -16.03B | -16.03B | -6.85B | 48.33B | -4.89B | 11.12B |
Sosei Group Technical Analysis
Negative
903.00
Price Trends
949.14
Negative
980.72
Negative
923.93
Negative
Market Momentum
-26.37
Positive
42.96
Neutral
35.75
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4565, the sentiment is Negative. The current price of 903 is above the 20-day moving average (MA) of 895.40, below the 50-day MA of 949.14, and below the 200-day MA of 923.93, indicating a bearish trend. The MACD of -26.37 indicates Positive momentum. The RSI at 42.96 is Neutral, neither overbought nor oversold. The STOCH value of 35.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4565.
Sosei Group Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | ¥27.41B | -62.27 | ― | ― | 3.43% | -53.59% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | ¥81.13B | -7.93 | -15.58% | ― | 10.88% | -327.56% | |
47 Neutral | ¥78.04B | -42.11 | ― | ― | 0.80% | 32.87% | |
41 Neutral | ¥122.97B | -34.27 | -6.88% | ― | -59.19% | -124.16% | |
41 Neutral | ¥71.74B | -21.91 | -44.85% | ― | ― | 31.36% |
* Healthcare Sector Average
JP:4565
Sosei Group
879.00
-1.00
-0.11%
JP:4587
Peptidream
973.70
-702.30
-41.90%
JP:4592
SanBio Co
971.00
-1,474.00
-60.29%
JP:4588
Oncolys BioPharma, Inc.
2,713.00
2,111.00
350.66%
JP:7774
Japan Tissue Engineering Co., Ltd.
782.00
222.00
39.64%
Sosei Group Corporate Events
Nxera Pharma Secures Fourth AbbVie Milestone in Neurology Collaboration
Jun 30, 2026
Nxera Pharma has reached a fourth research and development milestone under its multi-target discovery collaboration with AbbVie, triggering a US$10 million payment tied to the identification of validated and differentiated hit molecules against a ...
Nxera Pharma Joins OpenFold AI Consortium to Boost GPCR Drug Discovery
Jun 10, 2026
Nxera Pharma, a biopharma specialist in GPCR structure-based drug discovery, has built a Japan-centered commercial business and global RD footprint spanning the U.K., Switzerland and South Korea. Listed on the Tokyo Stock Exchange, it targets high...
Nxera Wins Fast-Track and Orphan Status in Korea for Duchenne Drug Vamorolone
Jun 1, 2026
Nxera has secured both Orphan Drug Designation and Global Innovative Products on Fast Track status from South Korea’s Ministry of Food and Drug Safety for vamorolone in Duchenne muscular dystrophy, formally recognizing the disease’s hi...
Nxera trims RSU share issuance after partial forfeiture
May 19, 2026
Nxera Pharma, a Tokyo-listed biopharma group, has adjusted the issuance of new shares under its No. 18 and No. 20 Restricted Stock Unit plans following partial forfeiture by four planned recipients. The total number of shares to be issued has been...
Nxera Pharma Spins Out Non-Core GPCR Program in NewCo Licensing and Series A Deal
May 11, 2026
Nxera Pharma has entered an out-licensing and investment agreement with a newly formed company to advance a non-core, preclinical GPCR-targeted program discovered using its NxWave platform. The deal grants NewCo an exclusive global license outside...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.